Abstract library

164 results for "non-cancer causes of death".
#3012 Causes of Death Following Neuroendocrine Tumors Diagnosis: A United States Population-Based Analysis
Introduction: Neuroendocrine tumors (NET) are heterogeneous in terms of prognosis based on location, grade, and stage.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: DR Mohamad Sonbol
#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#84 Rare association between pancreatic insulinoma and Graves's disease: fortune or misfortune?
Introduction: In spite of low frequency ( 4 cases in 1 million population), insulimoma is a significant pathology because hypoglycemia causes severe neurologic lesions and death.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Carmen Barbu
Authors: Barbu C, Stefan C, Miron A, Giulea C, ...
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#418 Chromogranin A (CgA) in the Diagnosis and Monitoring of Patients with Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NET): A Single-Institution Experience
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NET) are heterogeneous neoplasms with different malignancy. Plasma chromogranin A (CgA) may play an important role in predicting outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Sara Massironi
Keywords: CgA, GEP-NET
#537 Survival of Patients with Neuroendocrine Cancers in Ontario Over the Last 15 Years
Introduction: There has been an increased incidence of neuroendocrine tumors (NETs) in Ontario, Canada, over the last 15 years but little is known about trends in survival.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Cukier M, Liu N, Saskin R, ...
Keywords: survival
#1093 38 Years of Experience in a Single Centre on Neuroendocrine Pancreatico-Duodenal Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome
Introduction: Multiple Endocrine Neoplasia type 1 (MEN1) syndrome has an autosomal dominant transmission. Combination of tumors: parathyroid, pituitary and pancreatico-duodenal (PD) NETs. PD NETs in MEN1 syndrome show propensity for malignant degeneration.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Doctor Valbona Lico
#1157 Cardiac Evaluation as Part of the Initial Extension Studies in Neuroendocrine Tumors. Experience in a Multidisciplinary Team. ARGENTUM GROUP
Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine tumors and is screened for using echocardiography. Published case series showed that when cardiological evaluation is done at least 50% of the patients have CHD, and 33% had surgical indication.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Juan Manuel O'Connor
#1484 Neuroendocrine Tumors of the Appendix Are Probably Harmless Neoplasms
Introduction: Appendiceal neuroendocrine tumors (aNETs) have a 5-year survival rate between 74% and 95% according to recent data from Cancer Registry of Norway and the United States, respectively. However, in the daily clinical practice one almost never encounters patients suffering from aNETs with distant metastasis or dying of the disease.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Maike Nieser
Keywords: NET